JOHN ZAJECKA, M.D.

John Zajecka, M.D., is Associate Professor of Psychiatry and Clinical Director of the Depression Treatment and Research Center at Rush University Medical Center in Chicago, Illinois, and Rush North Shore Medical Center in Skokie, Illinois. Dr. Zajecka has also been in private practice since 1988.

Dr. Zajecka earned his MD at Loyola University Chicago Stritch School of Medicine. After graduating, he completed his internship and psychiatric residency at Rush.

Dr. Zajecka's expertise includes the study and treatment of depression, bipolar disorder and anxiety disorders. He has authored numerous publications and conducted research in affective disorders, anxiety disorders and schizophrenia. He has also done research and published extensively in the areas of treatment-resistant mood disorders, and safety and side effect issues related to psychotropic medications. He has a special interest in the management of treatment-resistant mood disorders, including the long-term outcomes of this population.

Dr. Zajecka serves on the scientific advisory boards for the National Depression and Bipolar Support Alliance and the American Foundation for Suicide Prevention, as well as for several pharmaceutical companies. He was past Co-Chairman of the Scientific Advisory Board Member for the Obsessive-Compulsive Foundation of Metropolitan Chicago and past President of the Midwest Chapter of the American Foundation for Suicide Prevention.

Dr. Zajecka received the Upjohn Young Investigators Award for Psychiatric Research and twice received the Special Recognition Award for Training Psychiatric Residents.

PEER-REVIEWED PUBLICATIONS:

Zajecka J, Goldstein C. Quetiapine vs. placebo: sexual dysfunction associated with escitalopram. (Pending submission)

Zajecka J, Goldstein C. The effect of quetiapine plus escitalopram on sexual function and satisfaction in outpatients with major depression: a placebo-controlled trial. (Pending submission)

Zajecka JM, Nierenberg A, Cantillon M, Entsuah R. Remission analysis of venlafaxine vs. paroxetine for major depression. (submitted for publication)

Bowden CL, Zajecka J, Stewart R, Evoniuk G, Leadbetter R: Concomitant use of lamotrigine and valproate in patients with bipolar disorder. Bipolar Disorders. (submitted for publication)

Raison CL, Woolwine BJ, Binongo J, Demitrashvili MF, Borisov AS, Weinreib R, Staab JP, Zajecka JM, Bruno CJ, Henderson MA, Reinus JF, Evans DL, Asnis GM, Miller AH. Paroxetine for prevention of depressive symptoms induced by interferon-alpha plus ribavirin for hepatitis c. (accepted for publication in Alimentary Pharmacology & Therapeutics)

Dunner DL, Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM. Preventing recurrent depression: long-term treatment for major depressive disorder. (accepted for publication in J Clin Psychiatry)

Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton R, Trivedi MH, Zajecka JM, Goldstein CG, Thase ME, Ahmed S, Pedersen R, Keller M. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bulletin. 42(3):5-20; 2009.

Zajecka J, Gutierrez S. Oral Divalproex Sodium Loading for Adolescent Outpatients With Acute Mania/Hypomania. J Clin Psychiatry 69:6: 1016-1018, June 2008.

Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 68(7):1014-1023, 2007.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 68(8):1246-1256, 2007.

Zajecka JM. Augmentation Strategies to Increase Antidepressant Tolerability. J Clin Psychiatry 68(10); 23-27, 2007.

Zajecka, JM. Calming the bipolar storm: treating acute mania and mixed episodes in patients with bipolar disorder. CNS Spectr 11:11(13); November, 2006.

Ninan PT, Koran LM, Kiev A, Davidson JRT, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Cristoph P, Mandel FS, Austin C: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry. 67:15-22, 2006.

Rao D, Zajecka J, Skubiak T. The modified rush sexual inventory: preliminary psychometric findings. Psychiatry Research. 137:175-181, 2005.

Rush JA, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 58:347-354, 2005.

Zajecka J, Goldstein C: Combining and augmenting: choosing the right therapies for treatment-resistant depression. Psychiatric Annals. 35(12):993-1000 December 2005.

Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF: A double-blind, randomized trial of st. john's wort, fluoxetine and placebo in major depressive disorder. J Clin Psychopharmacology. 25(5):441-447, October 2005.

Zajecka J: Treatment-resistant depression: benefits of tricyclic antidepressants. Primary Care Special Edition Volume 8; 2004.

Zajecka JM, Albano D. SNRIs in the management of acute major depressive disorder. J Clin Psychiatry 65(0):2004.

Zajecka JM: Acute mania. Psychiatric Annals 33:12: 786-795; December 2003.

Evans RM, Nierenberg AA, Zajecka JM. Major depressive disorder in primary care. American Medical Association Advisory Board, American Medical Association, December, 2003.

Zajecka JM: Treating depression to remission; J Clin Psychiatry 64(15):7-12; 2003.

Zajecka J: A 54-year-old man with bipolar type I disorder. Psychiatric Annals 33; 2003.

Zajecka J, Goldstein C: The side-effect profiles of antipsychotic medications. Primary Psychiatry 10(8):78-91; 2003.

Kelsey JE, Zajecka JM, Nelson JC: Treatment of pain and depression in the elderly. CNS News Special Edition 111-115; December 2003.

Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, Zajecka J, Schuh LM, Risser RC, Brown E, Baker RW. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 160(7):1263-71, Jul 2003.

Clayton A, Zajecka J, Ferguson J, et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18:151-156; 2003.

Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 64:288-294; 2003.

Ninan PT, Rush AJ, Crits-Cristoph P, Kornstein SG, Manber R, Thase ME, Trivedi MH, Rothbaum BO, Zajecka J, Borian FE, Keller MB. Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. J Clin Psychiatry 63(5):434-441; 2002.

Dunner DL, Laird LK, Zajecka J, Bailey L, Sussman N, Seabolt JL. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry 63(1):32-41; 2002.

Zajecka JM, Dunner DL, Hirschfeld R, Kornstein SG, et al. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. J Clin Psychiatry 63(8):709-716, 2002.

Gelenberg AJ, Trivedi MH, Rush AJ, Thase ME, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld R, Keitner GI, Zajecka J, et al. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biological Psychiatry; Nov. 2002.

Tummala R, Zajecka JM. Tricyclics: still solid performers for the savvy psychiatrist. Current Psychiatry 1(6), June 2002.

Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville K. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 63:1148-1155; 2002.

Zajecka JM, Miles W, Cobb T, Chen S, et al: Safety of abrupt discontinuation of nefazodone. J Clin Psychiatry 639(1):42-47; 2002.

Zajecka J, McEnany GW, Lusk KM: Antidepressant dosing and switching guidelines: focus on nefazodone. J Clin Psychiatry 63(1):42-47; 2002.

Zajecka J, Bailey L: Nefazodone: discontinuation issues and safety in chronic major depression. J Clin Psychiatry 63(1)36-38; 2002.

Zajecka J: Sexual side effects of antidepressants-management. J Clin Psychiatry 62(suppl 3):34-41; 2001.

Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan, EP: Intramuscular ziprasidone 2 mg vs 10 mg in the short-term management of agitated psychotic patients. J Clin Psychiatry; 62(1):12-18; 2001.

Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 62(6):413-420; 2001.

Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W: Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive disorder and major depressive disorder. Arch Gen Psychiatry 57(1):76; 2000.

Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462-1470; 2000.

Zajecka JM: Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 61(2):20-25; 2000.

Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342(20)1462-1470, 2000. Errata Statement: N Engl J Med 345(3):1462-1470; 2001.

Greco N, Zajecka JM: Evaluating and treating comorbid depression and anxiety in women. Women's Health in Primary Care 3(5):349-360; May 2000.

Meaden PM, Daniels RE, Zajecka J. Construct validity of life chart functioning scales for use in naturalistic studies of bipolar disorder. J Psychiatr Res 34(3):187-192; 2000.

Hirschfeld RMA, Williams JBW, Spitzer RL, Calabrese JR, Flynn L, Keck PE, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J: Development and validation of a screening instrument for bipolar spectrum disorder: The mood disorder questionnaire. Am J Psychiatry 157(11):1873-1875; November 2000.

Montgomery SA, Schatzberg AF, Guelfi JD, Kasper S, Nemeroff C, Swann A, Zajecka J. Pharmacotherapy of depression and mixed states in bipolar disorder. J Affect Disord 59(suppl 1):S39-S56; September 2000.

Michelson D, Asterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J, Sundell KL, Yongman K, Beasley CM: Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 156(8):1170-1176; 1999.

Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelseon D, Beasley CM: Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 60(6):389-394; June 1999.

Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C: Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study. J Clin Psychopharmacol 18(3):193-197; June 1998.

Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, Beasley CM, Michelson D, Roback P, Sundell K: Optimal length of continuation therapy in depression: A prospective assessment during fluoxetine long-term treatment. Am J Psychiatry 155(9):1247-1253; 1998.

Zajecka J, Tracy, KA, Mitchell S: Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry 58(7):291-297; July 1997.

Zajecka J: Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry 58(suppl 3):9-15; 1997.

Zajecka J, Mitchell S, Fawcett J: Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharm Bull 33(4):755-760, 1997.

Schatzberg, AF, Haddad P, Kaplan E, Lejoyeux M, Rosenbaum J, Young AH, Zajecka J: Serotonin reuptake inhibitor discontinuation syndrome: A hypothetical definition. J Clin Psychiatry 58(0):1-7; 1997.

Schatzberg, AF, Haddad P, Kaplan E, Lejoyeux M, Rosenbaum J, Young AH, Zajecka J: Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 58(0):1-6; 1997.

Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation. J Clin Psychiatry 58(suppl 7):37-40; 1997.

Zajecka J: Panic disorder and posttraumatic stress disorder. Psychiatric Annals 26(6):1-8; May 15, 1996.

Zajecka J: The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatients. J Clin Psychiatry 57(2):10-14; 1996.

Zajecka JM, Jeffriess H, Fawcett J: The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: A retrospective analysis. J Clin Psychiatry 56(8):338-343, 1995.

Zajecka J, Ross J: The management of comorbid anxiety and depression. J Clin Psychiatry 56(2):10-13, 1995.

Nyenhuis DL, Rao SM, Zajecka JM,Luchetta T, Bernardin L, Garron DC. Mood disturbance versus other symptoms of depression in multiple sclerosis. J Int Neuropsychol Soc 1(3):291-296; 1995.

Zajecka J, Fanelli J, Ross J, Kravitz H, Fawcett J: The efficacy of divalproex sodium vs. placebo in the treatment of panic disorder. Psychopharm Bull 30(4):735, 1994.

Heiligenstein JH, Faries DE, Zajecka JM, et al: Latency to rapid eye movement sleep as a predictor of response to fluoxetine and placebo in nonpsychotic depressed outpatients. Psychiatric Research 52:327-339, 1994.

Schaff M, Fawcett J, Zajecka J: Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry 54(10):380-384, 1993.

Zajecka J: Pharmacology, pharmacokinetics and safety issues of mood-stabilizing agents. Psychiatric Annals 23(2):79-85; February 1993.

Zajecka JM, Fawcett J: Reply to letter: Is tranylcypromine really metabolized to amphetamine? J Clin Psychiatry 53:12, Dec. 1992.

Zajecka JM, Fawcett: Susceptibility of spontaneous MAOI hypertensive episodes. J Clin Psychiatry (letter) 52:513-514, Dec. 1991.

Zajecka JM: Obsessive-compulsive disorder. Geriatric Medicine, 10(4):42-45, April 1991.

Fawcett J, Kravitz H, Zajecka J, Schaff M: CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol, 11(2):127-132, April 1991.

Zajecka JM, Fawcett J, Schaff M, Jeffriess H, Guy C: The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction. J Clin Psychiatry, 52(2):66-68; 1991.

Zajecka JM, Guy C, Solomon B: Theoretical implications of antidepressant drug fever. J Clin Psychopharmacology, 11(1):73-74, Feb. 1991.

Zajecka JM, Fawcett J: Innovative somatic treatments for depression. Psychiatric Medicine, 9(1):77-103; 1991.

Zajecka JM, Fawcett J: Antidepressant combination and potentiation. Psychiatric Medicine, 9(1):55-75; 1991.

Zajecka JM, Fawcett J, Guy C: Co-existing major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol, 10(2):April 1990 (letter).

Fawcett J, Zajecka JM, Kravitz H, Edwards J, Jeffriess H, Scorza E: Fluoxetine versus amitriptyline in adult outpatients with major depression. Current Therapeutic Research, 45(5), May 1989.

Ian Mackey, MS, PA-C

Aug. 2009 - Present
Subinvestigator
"A Placebo-controlled, Double-blind, Parallel-group, Individualized
Dosing Study of CONCERTA® in Adults with Attention Deficit
Hyperactivity Disorder to Optimize Balance of Benefit and Risk"
Ortho-McNeil Janssen Scientific Affairs

Aug. 2008 - Present
Subinvestigator
"A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to
Antidepressant Therapy (ADT) Among Outpatients with Major
Depressive Disorder Who Have Responded Inadequately to Prior ADT"
Bristol-Myers Squibb

Dec. 2008 - Present
Subinvestigator
"CRS106139: A Six-Week, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy,
Safety and Tolerability of GSK561679 Compared to Placebo in Female
Subjects Diagnosed with Major Depressive Disorder"
GlaxoSmithKline

June 2008 - Feb. 2009
Subinvestigator
"A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-
Dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus
Placebo in Acute Treatment of Adults with Major Depressive Disorder"
Takeda

June 2008 - Present
Subinvestigator
"A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to
Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Patients
with Depression Treatment Failure"
CNS Response

June 2008 - Present
Subinvestigator
"A 12-week, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial
of Ziprasidone as Monotherapy for Major Depressive Disorder"
Pfizer

Jan. 2007 - Feb. 2009
Subinvestigator
"An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-
Controlled, Parallel-Group, Multi-Center Study of the Efficacy, Safety and
Tolerability of Agomelatine 25mg and 50mg in the Treatment of Major Depressive Disorder Followed
by a 52-week, Open-Label Extension"
Novartis

Sept. 2006 - Present Subinvestigator "A Double-Blind, Placebo Controlled Study of 6(S)-5-MTHF among SSRI-Resistant
Outpatients with Major Depressive Disorder"
Pamlab

March 2006 - Present
Subinvestigator
"Treatment Resistant Depression Registry"
Cyberonics

March 2006 - Oct. 2007
Subinvestigator
"An Open-Label, Dose-Titration, Long-Term Safety Study to Evaluate Concerta
at Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg per day
in Adults with Attention Deficit Hyperactivity Disorder"
McNeil

March 2006 - Aug. 2007
Subinvestigator
"A Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Titration Study to Evaluate
the Efficacy and Safety of Concerta in Adults with Attention Deficit Hyperactivity Disorder at
Doses of 36 mg, 54 mg, 72 mg, 90 mg, or 108 mg per day"
McNeil

Feb. 2006 - June 2007
Subinvestigator
"A Multi-Center, Randomized-Withdrawal, Parallel-group,Placebo-Controlled, Phase III Study
of the Efficacy and Safety of Quetiapine Fumarate Sustained Release as Monotherapy in the
Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label
Stabilization Period"
AstraZeneca

Sept. 2005 - Dec. 2006
Subinvestigator
"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy
and Safety of Nalmefene HCl in the Treatment of Pathological Gambling"
Somaxon

April 2005 - July 2006
Subinvestigator
"A Randomized, Double-Blind, Parallel-Group Study of the Safety and Tolerability of XBD173
in Patients with Generalized Anxiety Disorder"
Novartis

Oct. 2004 - June 2005
Subinvestigator
"A Placebo-controlled, Double-blind, Randomized, Parallel Study of the Withdrawal Effects
of Chronic Daily and As Needed Dosing with Dapoxetine HCl in the Treatment of Premature Ejaculation"
Johnson & Johnson

Sept. 2004 - Jan. 2007
Subinvestigator
"A Long-Term Study of Aripiprazole in Patients with Major Depressive Disorder"
Bristol-Myers Squibb

Sept. 2004 - Aug. 2006
Subinvestigator
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and
Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients with
Major Depressive Disorder"
Bristol-Myers Squibb

Sept. 2004 - July 2006
Subinvestigator
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole Monotherapy
in the Treatment of Acutely Manic Patients with Bipolar I Disorder"
Bristol-Myers Squibb

Aug. 2004 - Aug. 2006
Subinvestigator
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole
in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode"
Bristol-Myers Squibb

July 2004 - Aug. 2006
Subinvestigator
"A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of
the Efficacy and Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to
Mood Stabilizers in Maintenance Treatment of Bipolar I Disorder in Adult Patients"
AstraZeneca

Feb. 2004 - Jan. 2008
Subinvestigator
"A Multicenter, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential
of Quetiapine Fumarate and Risperidone in the Long-Term Treatment of Patients with
Schizophrenia or Schizoaffective Disorder."
AstraZeneca

Jan. 2004 - July 2005
Subinvestigator
"Quetiapine as an Adjunct to SSRIs in the Treatment of Depression"
AstraZeneca

Oct. 2003 - Feb. 2005
Subinvestigator
"Duloxetine versus Escitalopram and Placebo in the Treatment of Patients
with Major Depression"
Eli Lilly

June 2003 - Present
Prescribing Clinician, Evaluator
"Prevention of Recurrence in Depression with Drugs and Cognitive Therapy"
National Institute of Mental Health

Feb. 2004 - Feb 2005
Subinvestigator
"An Open Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment
of Rapid Ejaculation"
Alza

June 2003 - Nov. 2005
Subinvestigator
"A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis (NCP) System
in Patients with Depression"
Cyberonics

June 2003 - July 2004
Subinvestigator
"Augmentation with Aripiprazole to Current Antidepressants in Depressed Patients Who
Are Partial Responders"
Bristol-Myers Squibb

June 2003 - Aug. 2004
Subinvestigator
"A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and
Efficacy of Dapoxetine HCL in the Treatment of Rapid Ejaculation"
Alza

Patients are drawn from the greater Ahicago / Northern Illinois area, Southern Wisconsin and Northeast Indiana.

PMA has worked with a wide and diverse patient population.

Psychiatry/Psychology